FDA Will Not Interfere With New Medicare CBD-Focused Initiative
Summarize
The Trump administration’s initiative to allow Medicare coverage for hemp-derived products up to $500 for eligible Medicare patients began on April 1, 2026. The Food and Drug Administration (FDA) says it will not interfere with its implementation. This is per a memo that FDA Commissioner Marty Makary wrote, which states that the FDA will not enforce certain sections of the Federal Food, Drug, and Cosmetic Act for orally administered, hemp-derived CBD products based solely on their containing CBD. The CBD products will have to meet the same requirements as dietary supplements, plus some specific requirements for CBD.
The main conditions for CBD products are included in the memo with the subject “Hemp-Derived Cannabidiol Products in Medical Research Models.”
- Must be manufactured, marketed, and labeled per requirements for dietary supplements, including containing a supplement facts panel on the product and claims of structure or function
- Cannot be contaminated
- Cannot be packaged or labeled in a way attractive to or marketed for children
- Must be provided to a beneficiary through a program authorized for medical items or services payable under Title XVIII of the Social Security Act and under a physician’s direction
By adhering to these guidelines, CBD brands avoid enforcement of laws that say a drug is misbranded if the label lacks adequate directions for use and that require premarket approval for new drugs. The FDA memo was issued the same day that the Centers for Medicare & Medicaid Services (CMS) implemented the new hemp product coverage program. Though the FDA guidance does not mention THC, the CMS program allows legal amounts of THC.
Cornbread Hemp is participating in the CMS program as a product supplier, and Jim Higdon, Co-founder and Chief Communications Officer, says that
“It’s very encouraging that the FDA appears to be allowing the Medicare pilot program to proceed. This is a sign that the executive branch is becoming comfortable with hemp-derived products…The historic implications of this moment are difficult to overstate. We could be entering a new era of cannabis legalization that has opened the door to insurance coverage and access for all.”
The federal government is really at odds right now. Though President Trump signed an order rescheduling marijuana to make it more accessible and CMS has launched a new program, Congress passed a law limiting THC to no more than 0.4 milligrams per container. The law takes effect in November 2026 and will make many CBD products illegal. Also complicating the process is the fact that a group of organizations against marijuana has filed a legal challenge to stop the CMS program.
The FDA’s decision not to enforce certain CBD restrictions and allowing the Centers for Medicare & Medicaid Services’ pilot program to proceed without interference feels like a common-sense recognition of market reality. Millions of people already use hemp-derived products regularly. Bringing these products into a regulated, physician-controlled program for seniors (and others) is far safer than leaving them to navigate the complex marketplace on their own.
Share this post
0